FIGURE 3. Progression-free survival in ER-positive breast carcinoma in responders and nonresponders after starting tamoxifen, with exclusion of patients with faint uptake on baseline scintigraphy. There is significant difference (P < 0.01) in progression-free survival between responders and nonresponders.